Patents Assigned to Penwest Pharmaceuticals Co.
-
Publication number: 20140271852Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: ApplicationFiled: May 29, 2014Publication date: September 18, 2014Applicant: PENWEST PHARMACEUTICALS CO.Inventors: Anand R. BAICHWAL, Philip A. GOLIBER, Anthony E. CARPANZANO, Thomas SCIASCIA, Donald DIEHL, II, Brian VOGLER, David VERBEL, Stanley AU
-
Publication number: 20140242166Abstract: Disclosed are sustained release oral solid dosage forms comprising a therapeutically effective amount of a medicament having a solubility of more than about 10 g/l; a pH modifying agent; and a sustained release matrix comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, said dosage form providing a sustained release of said medicament after oral administration to human patients.Type: ApplicationFiled: March 3, 2014Publication date: August 28, 2014Applicant: Penwest Pharmaceuticals Co.Inventors: Anand R. Baichwal, Troy W McCALL, Lirong LlU, Steve LABUDZINSKI
-
Publication number: 20130164350Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: ApplicationFiled: February 21, 2013Publication date: June 27, 2013Applicant: PENWEST PHARMACEUTICALS CO.Inventor: PENWEST PHARMACEUTICALS CO.
-
Patent number: 8394812Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: GrantFiled: May 23, 2008Date of Patent: March 12, 2013Assignee: Penwest Pharmaceuticals Co.Inventors: Anand R. Baichwal, Philip A. Goliber, Anthony E. Carpanzano, Thomas Sciascia, Donald Diehl, II, Brian Vogler, David Verbel, Stanley Au
-
Patent number: 8389008Abstract: A delayed release pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core.Type: GrantFiled: September 17, 2004Date of Patent: March 5, 2013Assignee: Penwest Pharmaceuticals Co.Inventors: Anand R. Baichwal, Paul Woodcock, Raymond Higgins, Jaclyn Cobb
-
Publication number: 20120101169Abstract: The present invention is directed to methods of providing anticoagulation effects in subjects in need thereof, comprising administering to the subjects at least twice a day compounds of the present invention, stereoisomers, and racemates thereof.Type: ApplicationFiled: July 11, 2011Publication date: April 26, 2012Applicant: Penwest Pharmaceuticals Co.Inventor: Amale HAWI
-
Publication number: 20110263720Abstract: The present invention is directed to a method of synthesizing a compound of Formula I: the method comprising oxidizing alpha-tocopherol with a metal salt oxidizing agent to form the compound of Formula I, wherein the stoichiometric ratio (mol/mol) of metal salt oxidizing agent/alpha-tocopherol is 1.6 to 4. The invention is also directed to a method of synthesizing a compound of Formula I, the method comprising (a) hydrolyzing alpha-tocopheryl acetate in the presence of a base; (b) neutralizing the hydrolyzing of (a), thereby forming alpha-tocopherol; and (c) oxidizing the alpha-tocopherol of (b) with a metal salt oxidizing agent to form the compound of Formula I, wherein the stoichiometric ratio (mol/mol) of metal salt oxidizing agent/alpha-tocopherol is 1.6 to 4.Type: ApplicationFiled: March 9, 2011Publication date: October 27, 2011Applicant: Penwest Pharmaceuticals Co.Inventors: Steven D. PAISLEY, Jason M. LePree, Amale Hawi, Michael Eckhoff
-
Publication number: 20090169587Abstract: A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a surfactant and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core.Type: ApplicationFiled: March 2, 2009Publication date: July 2, 2009Applicant: Penwest Pharmaceuticals Co.Inventors: Anand R. Baichwal, Paul Woodcock, Steve Labudzinski
-
Publication number: 20080085304Abstract: Robust sustained release formulations, solid dosage forms comprising robust sustained release formulations, and methods for making and using these formulations and solid dosage forms are provided. Robustness of the sustained release formulation is related to the particle size of the hydrophilic gum. Sustained release formulations resist dose-dumping when ingested with alcohol. The formulations are useful for treating a patient suffering from a condition, e.g., pain. The formulations comprise at least one drug. In one embodiment, the drug is an opioid, e.g., oxymorphone.Type: ApplicationFiled: October 10, 2006Publication date: April 10, 2008Applicant: Penwest Pharmaceuticals Co.Inventors: Anand R. Baichwal, Kevin Fitzmaurice, Steve Labudzinski
-
Publication number: 20080085303Abstract: Robust sustained release formulations, solid dosage forms comprising robust sustained release formulations, and methods for making and using these formulations and solid dosage forms are provided. Robustness of the sustained release formulation is related to the particle size of the hydrophilic gum. Sustained release formulations resist dose-dumping when ingested with alcohol. The formulations are useful for treating a patient suffering from a condition, e.g., pain. The formulations comprise at least one drug. In one embodiment, the drug is an opioid, e.g., oxymorphone.Type: ApplicationFiled: October 10, 2006Publication date: April 10, 2008Applicant: Penwest Pharmaceuticals Co.Inventors: Anand R. Baichwal, Kevin Fitzmaurice, Steve Labudzinski, Michelle Howard-Sparks, William Hein
-
Publication number: 20080085305Abstract: Robust sustained release formulations, solid dosage forms comprising robust sustained release formulations, and methods for making and using these formulations and solid dosage forms are provided. Robustness of the sustained release formulation is related to the particle size of the hydrophilic gum. Sustained release formulations resist dose-dumping when ingested with alcohol. The formulations are useful for treating a patient suffering from a condition, e.g., pain. The formulations comprise at least one drug. In one embodiment, the drug is an opioid, e.g., oxymorphone.Type: ApplicationFiled: October 10, 2006Publication date: April 10, 2008Applicant: Penwest Pharmaceuticals Co.Inventors: Anand R. Baichwal, Kevin Fitzmaurice, Steve Labudzinski, Michelle Howard-Sparks, William Hein
-
Publication number: 20070218137Abstract: Disclosed are sustained release oral solid dosage forms comprising a therapeutically effective amount of a medicament having a solubility of more than about 10 g/l; a pH modifying agent; and a sustained release matrix comprising a gelling agent, said gelling agent comprising a heteropolysaccharide gum and a homopolysaccharide gum capable of cross-linking said heteropolysaccharide gum when exposed to an environmental fluid, said dosage form providing a sustained release of said medicament after oral administration to human patients.Type: ApplicationFiled: March 27, 2007Publication date: September 20, 2007Applicant: Penwest Pharmaceuticals Co.Inventors: Anand Baichwal, Troy McCall, Lirong Liu, Steve Labudzinski
-
Publication number: 20070212414Abstract: The invention provides formulations that resist dose dumping in the presence of ethanol and methods of use thereof. The formulations can be used to prevent dose dumping, to increase safety of drugs, and to reduce abuse of drugs prone to such abuse. The formulations comprise at least one drug and a sustained release delivery system. In one embodiment, the drug is an opioid.Type: ApplicationFiled: March 8, 2006Publication date: September 13, 2007Applicant: Penwest Pharmaceuticals Co.Inventors: Anand Baichwal, Steve Labudzinski
-
Publication number: 20070196482Abstract: Disclosed in certain embodiments is a sustained release oral dosage form comprising an effective amount of torsemide or a pharmaceutically acceptable salt thereof and a sustained release excipient, wherein the dosage form provides a mean sodium (Na+) excretion and mean sodium (Na+) excretion rate as disclosed herein.Type: ApplicationFiled: December 15, 2006Publication date: August 23, 2007Applicant: Penwest Pharmaceuticals Co.Inventors: Pradeep Sanghvi, Sara Ketsela, Thomas Sciascia, Theodore Jaworski
-
Publication number: 20070140975Abstract: The invention provides opioid formulations having reduced potential for abuse, and having reduced potential for illegal sale and distribution. The opioid formulations of the invention comprise at least one opioid and a sustained release delivery system.Type: ApplicationFiled: February 9, 2007Publication date: June 21, 2007Applicant: Penwest Pharmaceuticals Co.Inventors: Anand Baichwal, Paul Woodcock, Troy McCall
-
Publication number: 20070048376Abstract: Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.Type: ApplicationFiled: August 24, 2006Publication date: March 1, 2007Applicant: Penwest Pharmaceuticals Co.Inventors: Anand Baichwal, Philip Goliber, Anthony Carpanzano, Thomas Sciascia, Donald Diehl, Brian Vogler
-
Publication number: 20060228413Abstract: In certain embodiments, the present invention is directed to a controlled release oral dosage form comprising: a therapeutically effective amount of venlafaxine or a pharmaceutically acceptable salt thereof and a controlled release material; wherein the amount of venlafaxine or pharmaceutically acceptable salt thereof released at 1 hour in 900 mL 0.1 N HCl (pH 1.5) with 40% EtOH using USP Apparatus II at 50 rpm is within 25% of the amount of venlafaxine or pharmaceutically acceptable salt thereof released at 1 hour in 900 mL 0.1 N HCl (pH 1.5) using USP Apparatus II at 50 rpm.Type: ApplicationFiled: February 28, 2006Publication date: October 12, 2006Applicant: Penwest Pharmaceuticals Co.Inventors: Sara Ketsela, Dean Dinicola, Anand Baichwal
-
Publication number: 20060193912Abstract: In certain embodiments, the present invention is directed to a controlled release oral dosage form comprising a therapeutically effective amount of O-desmethylvenlafaxine or a pharmaceutically acceptable salt thereof and a controlled release material; wherein the amount of O-desmethylvenlafaxine or pharmaceutically acceptable salt thereof released at 1 hour in 900 mL 0.1 N HCl (pH 1.5) with 40% EtOH using USP Apparatus II at 50 rpm is within 25% of the amount of O-desmethylvenlafaxine or pharmaceutically acceptable salt thereof released at 1 hour in 900 mL 0.1 N HCl (pH 1.5) using USP Apparatus II at 50 rpm.Type: ApplicationFiled: February 28, 2006Publication date: August 31, 2006Applicant: Penwest Pharmaceuticals Co.Inventors: Sara Ketsela, Dean Dinicola, Anand Baichwal
-
Publication number: 20060193911Abstract: In certain embodiments, the present invention is directed to a controlled release oral solid dosage form comprising a matrix comprising a therapeutically effective amount of venlafaxine, an active metabolite of venlafaxine, or a pharmaceutically acceptable salt thereof, dispersed in a cross-linked gelling agent, the matrix providing a controlled release of venlafaxine, active metabolite of venlafaxine, or salt thereof to provide 24 hour therapeutic plasma levels after oral administration to human patients.Type: ApplicationFiled: February 28, 2006Publication date: August 31, 2006Applicant: Penwest Pharmaceuticals Co.,Inventors: Sara Ketsela, Dean Dinicola, Anand Baichwal
-
Publication number: 20060105035Abstract: A sustained release pharmaceutical formulation includes a sustained release excipient including a gelling agent, an inert pharmaceutical diluent, an optional cationic cross-linking agent, and a medicament having moderate to poor solubility is disclosed. In certain embodiments, the sustained release excipient is granulated with a solution or suspension of a hydrophobic polymer in an amount effective to slow the hydration of the gelling agent when the formulation is exposed to an environmental fluid. In another embodiment, the tablet is coated with a hydrophobic polymer.Type: ApplicationFiled: January 17, 2006Publication date: May 18, 2006Applicant: Penwest Pharmaceuticals Co.Inventor: Anand Baichwal